BCL2 and breast carcinoma: To evaluate the in vivo effectiveness of BFC1108, mice bearing orthotopic breast cancer xenografts originating from high Bcl-2–expressing MDA-MB-231 cells (MDA-MB-231/Bcl-2) underwent a 4-week treatment administered via the intraperitoneal route.